SYMPOSIA

References:
Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org
Poster Presentations
1. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006; 114(1):1-7.
2. Chen WT, Yen DJ, Yu HY, Liao KK. Valproate-induced encephalopathy. Zhonghua Yi Xue Za Zhi (Taipei) 2001; 64(8):474-8.
3. Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 2007; 20(5):499-502.
4. Gurjar M, Singhal S, Baronia AK, Azim A, Poddar B. Valproate-induced hyperammonemic encephalopathy: A reminder of rare complication of valproate. J Emerg
Trauma Shock 2011; 4(2):321-2.
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S164-5
[PP-074] Ref. No: 274
Two cases of tardive dyskinesia associated with the use of paliperidone ER and
their management
Ömer Yanartaş, Yücel Yılmaz, İshak Saygılı, Selma Bozkurt Zincir, Ümit Başar Semiz
Erenkoy Mental Health and Disorders Training and Research Hospital, Istanbul, Turkey
E-mail: yanartas2005@yahoo.com
Paliperidone is an extended-release (ER) medication used in the treatment of schizophrenia and the recommended dose range is 3-12
mg/day (1). Tardive dyskinesia (TD) associated with the use of antipsychotics is characterized by involuntary choreic-athetoid movements
occurring in the late stages of the treatment. Choreathetoid movements mostly occur around the mouth and face and athetoid
movements alone mostly occur on the head-neck and pelvis (2, 3). We hereby present two cases of perioral dyskinesia who were using
paliperidone, and discuss their response to the treatment.
Both patients were females in their 20s and had been diagnosed with paranoid schizophrenia according to the DSM-IV-TR diagnostic
criteria. Both patients had been using olanzapine before being switched to paliperidone ER. Olanzapine treatment had been discontinued
due to side effects and treatment failure. The durations of paliperidone ER use were 9 months and 1 year, respectively; the doses of
paliperidone ER were 9 and 12 mg/day that is consistent with the literature in terms of side effect risk (4). In one of the cases, the
occurrence of side effects in combination with a psychotic exacerbation led to a change in antipsychotic drug therapy. In the other case,
the drug was not discontinued due to the remission of initial psychotic symptoms and satisfaction of the patient with the treatment;
however, the drug dose was reduced. In the treatment of TD associated with the use of paliperidone ER, one case responded to vitamin
E 400 MU/day and omega 3 fatty acids while the other was administered propranolol 40 mg/day and clonazepam 1 mg/day. After one
month, the scores of both patients on the extrapyramidal symptoms assessment scale were markedly reduced. The patient who had the
psychotic exacerbation also had a history of childhood trauma, which we feel had negatively influenced the course of the treatment.
Young age and female sex, and drug use for more than 6 months may increase the risk of TD in patients taking paliperidone; the use of
vitamin E, omega 3 fatty acids, propranolol, and clonazepam may lead to a significant improvement in symptoms.
Key words: Extrapyramidal side effects, paliperidone, tardive dyskinesia
References:
1. Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data Neuropsychiatric Disease and Treatment 2007:3(6) 869–883.
2. Kaplan HI, Sadock BJ Synopsis of Psychiatry: Eighth ed. Baltimore: Williams & Wilkins, 1998
3. Bernstein JG. Drug Therapy in Psychiatry. Third ed. St.Louis: Mosby-Year Book, 1995
4. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment
of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008 May;69(5):817-29.
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S165
S165